IXO Private Equity

News

Cerenis Therapeutics adds $13.9M for plaque-reversing heart drug

Ann Arbor, Michigan, biopharmaceutical company Cerenis Therapeutics added $13.9 million to a July investment round that it will use to continue clinical trials of a drug to treat heart disease. Cerenis will use its latest investment to do Phase II clinical trial development of CER-001, which mimics high-density lipid ("good") cholesterol and can rapidly reverse atherosclerotic plaque.